PARP Inhibitors Market to Register Immense Growth by 2034 Owing to Wider Opportunity in Multiple Indications with HRR (BRCA) Gene Mutations and Increasing Cost of Therapy of Leading PARP Inhibitors in the US | DelveInsight

The PARP inhibitors market is anticipated to experience substantial growth in the coming years. This growth is driven by label expansion of leading PARP inhibitors in various indications, a rising number of cancer diagnoses mainly metastatic breast, ovarian, prostate, and pancreatic…